- IN₹306.28bn
- IN₹278.92bn
- IN₹56.17bn
- 93
- 15
- 61
- 61
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 30.21 | ||
| PEG Ratio (f) | 1.25 | ||
| EPS Growth (f) | 31.73% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.35 | ||
| Price to Tang. Book | 3.48 | ||
| Price to Free Cashflow | 58.84 | ||
| Price to Sales | 5.45 | ||
| EV to EBITDA | 21.98 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.22% | ||
| Return on Equity | 7.82% | ||
| Operating Margin | 15.86% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 34,628.76 | 44,007.08 | 36,246.01 | 56,647.22 | 56,165.04 | 64,059 | 71,414.96 | 16.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +35.45 | +16.93 | -31.76 | -6.71 | -9.56 | +36.04 | +23.68 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.
Directors
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- March 20th, 1978
- Public Since
- November 20th, 2020
- No. of Employees
- 4,217
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
National Stock Exchange of India- Shares in Issue
- 164,756,423
- Address
- Survey No.143-148,150&151, HYDERABAD, 500043
- Web
- https://glandpharma.com/
- Phone
- +91 4030510999
- Contact
- Sampath Pallerlamudi
- Auditors
- Deloitte Haskins & Sells
Upcoming Events for GLAND
Dividend For GLAD.NS - 18.0000 INR
Gland Pharma Ltd Annual Shareholders Meeting
Q2 2026 Gland Pharma Ltd Earnings Release
Similar to GLAND
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
What is the Gland Pharma share price?
As of Today at 20:51 UTC, shares in Gland Pharma are trading at IN₹1,859.00. This share price information is delayed by 15 minutes.
How has the Gland Pharma share price performed this year?
Shares in Gland Pharma last closed at IN₹1,859.00 and the price had moved by -9.38% over the past 365 days. In terms of relative price strength the Gland Pharma share price has underperformed the S&P BSE 100 Index by -11.2% over the past year.
What are the analyst and broker recommendations for Gland Pharma?
The overall consensus recommendation for Gland Pharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Gland Pharma dividend yield?
The Gland Pharma dividend yield is 0.97% based on the trailing twelve month period.
Does Gland Pharma pay a dividend?
Last year, Gland Pharma paid a total dividend of IN₹18.00, and it currently has a trailing dividend yield of 0.97%.Looking ahead, shares in Gland Pharma are due to go ex-dividend on 2025-08-14 and the next dividend pay date is 2025-09-27.
When does Gland Pharma next pay dividends?
Gland Pharma are due to go ex-dividend on 2025-08-14 and the next dividend pay date is 2025-09-27. The historic dividend yield on Gland Pharma shares is currently 0.97%.
How do I buy Gland Pharma shares?
To buy shares in Gland Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Gland Pharma?
As of the previous close price of IN₹1,859.00, shares in Gland Pharma had a market capitalisation of IN₹306.28bn.
Where are Gland Pharma shares listed?
Here are the trading details for Gland Pharma:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: GLAND
What kind of share is Gland Pharma?
Based on an overall assessment of its quality, value and momentum Gland Pharma is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Gland Pharma share price forecast for 2025?
The analyst consensus target price for shares in Gland Pharma is IN₹1,632.82. That is 12.17% below the last closing price of IN₹1,859.00.
Analysts covering Gland Pharma currently have a consensus Earnings Per Share (EPS) forecast of IN₹57.68 for the next financial year.
Find out moreWhat is the trend in the Gland Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Gland Pharma. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -4.48%.
As of the last closing price of IN₹1,859.00, shares in Gland Pharma were trading +12.92% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Gland Pharma PE Ratio?
The Gland Pharma PE ratio based on its reported earnings over the past 12 months is 30.21. The shares last closed at IN₹1,859.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Gland Pharma?
Gland Pharma's management team is headed by:
- P. V. N. Raju - CHM
- Ravi Penmetsa - VCH
- Jia Ai Zhang - NED
- Naina Kidwai - IND
- Udo Vetter - NID